Delphinus Medical Technologies, founded in Plymouth, United States, is dedicated to revolutionizing breast cancer screening through innovative imaging solutions. The company's core mission is to enhance early detection of breast cancer, particularly in women with dense breast tissue, by providing advanced diagnostic tools. Their flagship product, SoftVue™ 3D Whole Breast Ultrasound Tomography, is FDA PMA approved and designed specifically for dense breast screening. Delphinus aims to address the limitations of traditional mammography, which often misses cancers in dense breasts, thereby improving diagnostic accuracy and patient outcomes.

Notable figures associated with Delphinus Medical Technologies include key investors and medical professionals who support the company's vision of transforming breast cancer diagnostics. The company's significant achievement includes obtaining FDA PMA approval for SoftVue™, a milestone that underscores its commitment to clinical excellence and innovation. Delphinus has made a substantial impact on the healthcare industry by providing a reliable alternative to mammography, thereby increasing the chances of early detection and treatment of breast cancer in women with dense breast tissue.